Abstract
Abstract Background The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-gen...
Cite
CITATION STYLE
APA
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., … Giovannoni, G. (2024). Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine, 390(7), 589–600. https://doi.org/10.1056/nejmoa2309439
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free